Helix BioPharma (TSE:HBP) has released an update.
Helix BioPharma Corp., a biopharmaceutical company focused on developing immune-oncology therapies, has announced a consolidation of its common shares. Shareholders will see a shift from five pre-consolidation shares to one post-consolidation share, pending Toronto Stock Exchange approval, effective August 16, 2024. The move aims to streamline the company’s share structure and is expected to leave Helix with 49,021,536 common shares in the market.
For further insights into TSE:HBP stock, check out TipRanks’ Stock Analysis page.
